Knockdown of ANXA3, which is highly expressed in NF2−/− tumours irrespective of specific NF2 mutations (Fig. 4d, Supplementary Table S2 for clinical data), reduces proliferation as demonstrated by at least two proliferation assays (Fig. 6c and d). This evidence concerns the gene ANXA3 and neoplasm.